A Phase 3 interventional study of bupivacaine liposome injectable suspension and Bupivacaine Hydrochloride in Knee Osteoarthritis and Pain Management, sponsored by Pacira Pharmaceuticals, Inc. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-24.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Osteoarthritis, Knee by Pacira BioSciences, Inc. — 2 open to participants now, 3 under way, none of them phase 3. Osteoarthritis, Knee · Pacira BioSciences, Inc..
Among the 16 studies in Osteoarthritis, Knee by Pacira BioSciences, Inc., this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2022, is one of 4 in phase 3, and was the 14th registered.
3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.
Browse Osteoarthritis, Knee studies →2 of the 16 studies in Osteoarthritis, Knee by Pacira BioSciences, Inc. are open now, in 1 country. Recruiting first, the newest first:
Pacira Pharmaceuticals, Inc · Sites in United States
Ages 45–80
Pacira Pharmaceuticals, Inc · Sites in United States
By country, each count listing its studies:
Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 4
First in 2010; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 167 is above the median of 68 across 2,717 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 135 across the 15 interventional studies, 10,000 across the 1 observational. Of the 13 that completed or were terminated, 12 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
1 of the studies in Osteoarthritis, Knee by Pacira BioSciences, Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06884865Pacira Pharmaceuticals, IncA Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Osteoarthritis, Knee by Pacira BioSciences, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare magnitude of postsurgical analgesic effect in different groups following a single dose of study drug when administered via adductor canal block in subjects undergoing primary unilateral total knee arthroplasty.
This is a Phase 3, multicenter, randomized, double-blind, active-controlled study in approximately 160 subjects undergoing primary unilateral TKA under spinal anesthesia. The study will have 2 cohorts, enrolling in parallel.
Cohort 1 -Pharmacokinetics (PK), pharmacodynamics (PD), Efficacy, and Safety, Cohort 2 -Efficacy and Safety
An adaptive study design will be used in this study. An interim analysis to evaluate the sample size assumptions and evaluate futility will occur when a total of approximately 80 subjects (40 subjects in each arm) combined from either Cohort 1 or Cohort 2 have enrolled and provided complete assessment data for the primary efficacy outcome.
The time from study drug administration until the end of participation is Post-operative day (POD) 14 (±3 days). Therefore, subjects may participate in the study for up to 62 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Given the coronavirus disease 2019 (COVID-19) pandemic, if there is a concern about a subject's recent or potential exposure to COVID-19, or if the subject is not medically fit/cleared for surgery due to suspected COVID-19 illness/symptoms, the subject must be excluded per Exclusion criterion #13.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subjects randomized to this treatment arm will receive 10 mL (133 mg) EXPAREL admixed with 10 mL (50 mg) 0.5% bupivacaine HCl
Drug: bupivacaine liposome injectable suspension
subjects randomized to this treatment arm will receive 10 mL (50 mg) 0.5% bupivacaine HCl mixed with 10 mL normal saline
Drug: Bupivacaine Hydrochloride
subjects randomized to this treatment arm will receive 10 mL (133 mg) EXPAREL admixed with 10 mL (50 mg) 0.5% bupivacaine HCl
Drug: bupivacaine liposome injectable suspension
subjects randomized to this treatment arm will receive 10 mL (50 mg) 0.5% bupivacaine HCl mixed with 10 mL normal saline
Drug: Bupivacaine Hydrochloride
Adductor canal block with EXPAREL
Also known as: EXPAREL
Adductor Canal Block with bupivacaine HCl
NRS Scores Through 96 Hours Post-surgery
The numeric rating scale pain intensity scores ranging from 0 to 10, where 0 equals no pain and 10 equals the worst possible pain, from 0 to 96 hours post-surgery. For each subject, the area under the curve was derived using the trapezoidal rule on the pain scores adjusted for opioid pain medication using the observed and imputed values. Area under the curve started with the first pain assessment obtained after surgery and use all subsequent pain assessments up to 96 hours post-surgery. Pain scores were taken at 5 interval point: 0 hours, 24 hours, 48 hours, 72 hours, and 96 hours. There were also unscheduled pain scores measured before opioid consumption also included in the area under the curve calculation. The area under the curve ranged from 0 to 960. Higher scores represent a worse outcome.
Time frame: 0 to 96 hours post-surgery
Postsurgical Opioid Consumption Through 96 Hours Post-surgery
Total postsurgical opioid consumption in mg oral morphine equivalents (OMED) from 0 to 96 hours post-surgery.
Time frame: 0 to 96 hours post-surgery
Time to First Opioid
Time to first opioid consumption post-surgery
Time frame: 0 to 96 hours post-surgery
NRS Scores
Worst and average NRS pain intensity scores at 24h, 48h, 72h and 96h from the end of surgery Worst and average pain intensity scores on a numeric rating scale ranging from 0 to 10, where 0 equals no pain and 10 equals the worst possible pain, from 0 to 24 hours, 24 to 48 hours, 48 to 72 hours, and 72 to 96 hours. Mean scores at each timepoint are provided. The total range is 0 (no pain) to 10 (worst possible pain). Higher values on the scale represent worst outcome
Time frame: 0-24hours, 24-48hours, 48-72hours, 72-96hours
Participants were recruited based on physician referral at 6 sites between January 2022 and July 2022. The first participant was enrolled on January 18, 2022 and the last participant was enrolled in June 08, 2022.
| Milestone | Cohort 1 + 2: EXPAREL Admix Arm | Cohort 1 + 2: Bupivacaine HCl Arm |
|---|---|---|
| Started | 85 | 82 |
| Completed | 84 | 77 |
| Not completed | 1 | 5 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Failure to meet continuation criteria | 0 | 1 |
The numeric rating scale pain intensity scores ranging from 0 to 10, where 0 equals no pain and 10 equals the worst possible pain, from 0 to 96 hours post-surgery. For each subject, the area under the curve was derived using the trapezoidal rule on the pain scores adjusted for opioid pain medication using the observed and imputed values. Area under the curve started with the first pain assessment obtained after surgery and use all subsequent pain assessments up to 96 hours post-surgery. Pain scores were taken at 5 interval point: 0 hours, 24 hours, 48 hours, 72 hours, and 96 hours. There were also unscheduled pain scores measured before opioid consumption also included in the area under the curve calculation. The area under the curve ranged from 0 to 960. Higher scores represent a worse outcome.
| units on a scale*hours | Cohort 1 + 2 EXPAREL ADMIX ARM | Cohort 1 + 2 BUPIVACAINE HCI ARM |
|---|---|---|
| NRS Scores Through 96 Hours Post-surgery | 594.4 ± 191.65 | 650.1 ± 178.95 |
Total postsurgical opioid consumption in mg oral morphine equivalents (OMED) from 0 to 96 hours post-surgery.
| milligrams oral morphine equivalents | Cohort 1 + 2 EXPAREL ADMIX ARM | Cohort 1 + 2 BUPIVACAINE HCI ARM |
|---|---|---|
| Postsurgical Opioid Consumption Through 96 Hours Post-surgery | 109.19 ± 54.420 | 136.91 ± 48.284 |
Time to first opioid consumption post-surgery
| hours | Cohort 1 + 2 EXPAREL ADMIX ARM | Cohort 1 + 2 BUPIVACAINE HCI ARM |
|---|---|---|
| Time to First Opioid | 4.15 (3.80 to 4.83) | 3.63 (2.98 to 4.05) |
Worst and average NRS pain intensity scores at 24h, 48h, 72h and 96h from the end of surgery Worst and average pain intensity scores on a numeric rating scale ranging from 0 to 10, where 0 equals no pain and 10 equals the worst possible pain, from 0 to 24 hours, 24 to 48 hours, 48 to 72 hours, and 72 to 96 hours. Mean scores at each timepoint are provided. The total range is 0 (no pain) to 10 (worst possible pain). Higher values on the scale represent worst outcome
| units on a scale | Cohort 1 + 2 EXPAREL ADMIX ARM | Cohort 1 + 2 BUPIVACAINE HCI ARM |
|---|---|---|
| Worst pain at 24 hours | 8.6 ± 1.63 | 8.7 ± 1.77 |
| Worst pain at 48 hours | 7.9 ± 1.98 | 8.2 ± 1.81 |
| Worst pain at 72 hours | 6.8 ± 2.33 | 7.5 ± 2.14 |
| Worst pain at 96 hours | 6.6 ± 2.24 | 7.0 ± 2.34 |
| Average pain at 24 hours | 6.7 ± 1.89 | 6.6 ± 2.00 |
| Average pain at 48 hours | 5.8 ± 2.03 | 6.2 ± 1.84 |
| Average pain at 72 hours | 5.2 ± 2.14 | 5.7 ± 2.08 |
| Average pain at 96 hours | 4.8 ± 2.18 | 5.2 ± 1.96 |
Collected over Treatment-emergent adverse events were collected from the date and time on or after the start date and time of study drug administration through post-operative Day 14. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 + 2 EXPAREL ADMIX ARM | 0/85 (0%) | 3/85 (3.5%) | 77/85 (90.6%) |
| Cohort 1 + 2 BUPIVACAINE HCI ARM | 0/81 (0%) | 3/81 (3.7%) | 71/81 (87.7%) |
| Event | Cohort 1 + 2 EXPAREL ADMIX ARM | Cohort 1 + 2 BUPIVACAINE HCI ARM |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/85 | 1/81 |
| Atrial fibrillationCardiac disorders | 0/85 | 1/81 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/85 | 1/81 |
| AngioedemaSkin and subcutaneous tissue disorders | 0/85 | 1/81 |
| TachycardiaCardiac disorders | 1/85 | 0/81 |
| PneumoniaInfections and infestations | 1/85 | 0/81 |
| Post procedural haematomaInjury, poisoning and procedural complications | 1/85 | 0/81 |
| Event | Cohort 1 + 2 EXPAREL ADMIX ARM | Cohort 1 + 2 BUPIVACAINE HCI ARM |
|---|---|---|
| NauseaGastrointestinal disorders | 34/85 | 30/81 |
| ConstipationGastrointestinal disorders | 30/85 | 31/81 |
| InsomniaPsychiatric disorders | 5/85 | 13/81 |
| HeadacheNervous system disorders | 13/85 | 2/81 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 11/85 | 9/81 |
| HypotensionVascular disorders | 3/85 | 8/81 |
| VomitingGastrointestinal disorders | 5/85 | 6/81 |
| PruritusSkin and subcutaneous tissue disorders | 6/85 | 4/81 |
| TachycardiaCardiac disorders | 4/85 | 5/81 |
| HypertensionVascular disorders | 5/85 | 4/81 |
Number of all participants for whom baseline characteristics were measured, in each cohort and in the entire study population (total)
| Age, Categorical(Participants) | Cohort 1 + 2: EXPAREL Admix Arm | Cohort 1 + 2: Bupivacaine HCl Arm | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 54 | 53 | 107 |
| >=65 years | 31 | 28 | 59 |
| Age, Continuous(years) | Cohort 1 + 2: EXPAREL Admix Arm | Cohort 1 + 2: Bupivacaine HCl Arm | Total |
|---|---|---|---|
| Mean | 62.00 ± 7.049 | 62.21 ± 8.402 | 62.10 ± 7.716 |
| Sex: Female, Male(Participants) | Cohort 1 + 2: EXPAREL Admix Arm | Cohort 1 + 2: Bupivacaine HCl Arm | Total |
|---|---|---|---|
| Female | 42 | 39 | 81 |
| Male | 43 | 42 | 85 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 + 2: EXPAREL Admix Arm | Cohort 1 + 2: Bupivacaine HCl Arm | Total |
|---|---|---|---|
| Hispanic or Latino | 21 | 12 | 33 |
| Not Hispanic or Latino | 64 | 66 | 130 |
| Unknown or Not Reported | 0 | 3 | 3 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 + 2: EXPAREL Admix Arm | Cohort 1 + 2: Bupivacaine HCl Arm | Total |
|---|---|---|---|
| Race — White | 67 | 63 | 130 |
| Race — Black/African American | 14 | 15 | 29 |
| Race — Other | 4 | 3 | 7 |
| Region of Enrollment(participants) | Cohort 1 + 2: EXPAREL Admix Arm | Cohort 1 + 2: Bupivacaine HCl Arm | Total |
|---|---|---|---|
| United States | 85 | 81 | 166 |
| ASA classification(Participants) | Cohort 1 + 2: EXPAREL Admix Arm | Cohort 1 + 2: Bupivacaine HCl Arm | Total |
|---|---|---|---|
| ASA 1 | 21 | 21 | 42 |
| ASA 2 | 62 | 56 | 118 |
| ASA 3 | 2 | 3 | 5 |
| Unknown | 0 | 1 | 1 |
| Body Mass Index(kilograms/m^2) | Cohort 1 + 2: EXPAREL Admix Arm | Cohort 1 + 2: Bupivacaine HCl Arm | Total |
|---|---|---|---|
| Mean | 31.43 ± 4.786 | 32.74 ± 4.955 | 32.07 ± 4.899 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2022 to primary completion in Jul 2022, 5 months.
Results were first posted in Oct 2024, 2 years 3 months after primary completion.
Of 65 industry-sponsored phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 27. This study's 5 months is below that.
Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal Bupivacaine